Polo-like kinase inhibitor Ro5203280 has potent antitumor activity in nasopharyngeal carcinoma

Molecular Cancer Therapeutics

Volumn 12, Issue 8, 2013, Pages 1393-1401

  Cheung, Arthur Kwok Leung ^a   Ip, Joseph Chok Yan ^a   Lung, Hong Lok ^a   Wu, Jim Zhen ^b   Tsao, Sai Wah ^a   Lung, Maria Li ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b Roche Pharma Research and Early Development   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHECKPOINT KINASE 2; LIPOCORTIN 5; POLO LIKE KINASE 1; POLO LIKE KINASE INHIBITOR; RO 5203280; SECURIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FLUORESCENCE ACTIVATED CELL SORTING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MITOSIS; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZAMIDES; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HETEROCYCLIC COMPOUNDS, 2-RING; HUMANS; MICE; NASOPHARYNGEAL NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; SPINDLE APPARATUS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84882236446     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1219     Document Type: Article

References (47)

1. Hui AB, Or YY, Takano H, Tsang RK, To KF, Guan XY, et al. Array-based comparative genomic hybridization analysis identified cyclin D1 as a target oncogene at 11q13.3 in nasopharyngeal carcinoma. Cancer Res 2005;65:8125-33.
2. Andrysik Z, Bernstein WZ, Deng L, Myer DL, Li YQ, Tischfield JA, et al. The novel mouse polo-like kinase 5 responds to DNA damage and localizes in the nucleolus. Nucleic Acids Res 2010;38:2931-43.
3. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321-30.
4. Yuan J, Horlin A, Hock B, Stutte HJ, Rubsamen-Waigmann H, Strebhardt K. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997;150:1165-72.
5. Renner AG, Dos Santos C, Recher C, Bailly C, Creancier L, Kruczynski A, et al. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells. Blood 2009;114:659-62.
6. Eckerdt F, Yuan J, Strebhardt K. Polo-like kinases and oncogenesis. Oncogene 2005;24:267-76.
7. Takai N, Hamanaka R, Yoshimatsu J, Miyakawa I. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287-91.
8. Shi W, Alajez NM, Bastianutto C, Hui AB, Mocanu JD, Ito E, et al. Significance of Plk1 regulation by miR-100 in human nasopharyngeal cancer. Int J Cancer 2010;126:2036-48.
9. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: A novel marker of metastatic disease. J Cutan Pathol 2002;29:354-8.
10. Watanabe N, Arai H, Nishihara Y, Taniguchi M, Hunter T, Osada H. Mphase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. Proc Natl Acad Sci U S A 2004;101:4419-24.
11. Tominaga Y, Wang A, Wang RH, Wang X, Cao L, Deng CX. Genistein inhibits Brca1 mutant tumor growth through activation ofDNA damage checkpoints, cell cycle arrest, and mitotic catastrophe. Cell Death Differ 2007;14:472-9.
12. van Vugt MA, Smits VA, Klompmaker R, Medema RH. Inhibition of Polo-like kinase-1 by DNA damage occurs in an ATM-or ATR-dependent fashion. J Biol Chem 2001;276:41656-60.
13. Lane HA, Nigg EA. Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 1996;135:1701-13.
14. Kotani S, Tugendreich S, Fujii M, Jorgensen PM, Watanabe N, Hoog C, et al. PKA and MPF-activated polo-like kinase regulate anaphasepromoting complex activity and mitosis progression. Mol Cell 1998;1: 371-80.
15. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, et al. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 2011;17:3420-30.
16. Jimeno A, Li J, Messersmith WA, Laheru D, Rudek MA, Maniar M, et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 2008;26:5504-10.
17. Mross K, Frost A, Steinbild S, Hedbom S, Rentschler J, Kaiser R, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol 2008;26:5511-7.
18. Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, et al. NMSP937, an orally available, specific, small molecule Polo-Like Kinase 1 inhibitor with antitumor activity in solid and haematological malignancies. Mol Cancer Ther 2012;11:1006-16.
19. Cheung ST, Huang DP, Hui AB, Lo KW, Ko CW, Tsang YS, et al. Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer 1999;83:121-6.
20. Glaser R, Zhang HY, Yao KT, Zhu HC, Wang FX, Li GY, et al. Two epithelial tumor cell lines (HNE-1 and HONE-1) latently infected with Epstein-Barr virus that were derived from nasopharyngeal carcinomas. Proc Natl Acad Sci U S A 1989;86:9524-8.
21. Huang DP, Ho JH, Poon YF, Chew EC, Saw D, Lui M, et al. Establishment of a cell line (NPC/HK1) from a differentiated squamous carcinoma of the nasopharynx. Int J Cancer 1980;26:127-32.
22. Yip YL, Tsang CM, Deng W, Cheung PY, Jin Y, Cheung AL, et al. Expression of Epstein-Barr virus-encoded LMP1 and hTERT extends the life span and immortalizes primary cultures of nasopharyngeal epithelial cells. J Med Virol 2010;82:1711-23.
23. Cao SX, Feher V, Ichikawa T, Jones B, Kaldor S, Kiryanov A, et al. inventors. Takeda Pharmaceutical Company Limited, assignee. WO2009/042711. 2009 Apr 2.
24. Law EW, Cheung AK, Kashuba VI, Pavlova TV, Zabarovsky ER, Lung HL, et al. Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. Oncogene 2012;31:728-38.
25. Cheng Y, Poulos NE, Lung ML, Hampton G, Ou B, Lerman MI, et al. Functional evidence for a nasopharyngeal carcinoma tumor suppressor gene that maps at chromosome 3p21.3. Proc Natl Acad Sci U S A 1998;95:3042-7.
26. Lung HL, Cheung AKL, Xie D, Cheng Y, Kwong FM, Murakami Y, et al. TSLC1 is a tumor suppressor gene associated with metastasis in nasopharyngeal carcinoma. Cancer Res 2006;66:9385-92.
27. Cheung AK, Ko JM, Lung HL, Chan KW, Stanbridge EJ, Zabarovsky E, et al. Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis. Proc Natl Acad Sci U S A 2011;108:8390-5.
28. Cheung AK, Lung HL, Ko JM, Cheng Y, Stanbridge EJ, Zabarovsky ER, et al. Chromosome 14 transfer and functional studies identify a candidate tumor suppressor gene, mirror image polydactyly 1, in nasopharyngeal carcinoma. Proc Natl Acad Sci U S A 2009;106: 14478-83.
29. Cheung AK, Lung HL, Hung SC, Law EW, Cheng Y, Yau WL, et al. Functional analysis of a cell cycle-associated, tumor-suppressive gene, protein tyrosine phosphatase receptor type G, in nasopharyngeal carcinoma. Cancer Res 2008;68:8137-45.
30. DePinto W, Chu XJ, Yin X, Smith M, Packman K, Goelzer P, et al. In vitro and in vivo activity of R547: A potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials. Mol Cancer Ther 2006;5:2644-58.
31. Steegmaier M, Hoffmann M, Baum A, Lenart P, Petronczki M, Krssak M, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007;17:316-22.
32. Frost A, Mross K, Steinbild S, Hedbom S, Unger C, Kaiser R, et al. Phase i study of the Plk1 inhibitor BI 2536 administered intravenously on three consecutive days in advanced solid tumours. Curr Oncol 2012;19:e28-35.
33. Su Y, Vilgelm AE, Kelley MC, Hawkins O, Liu Y, Boyd KL, et al. RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012;18:2184-98.
34. Harris PS, Venkataraman S, Alimova I, Birks DK, Donson AM, Knipstein J, et al. Polo-like kinase 1 (PLK1) inhibition suppresses cell growth and enhances radiation sensitivity in medulloblastoma cells. BMC Cancer 2012;12:80.
35. Shi JQ, Lasky K, Shinde V, Stringer B, Qian MG,Liao D, et al. MLN0905, a small-molecule PLK1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther 2012;11:2045-53.
36. Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, et al. Arandomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naive patients with unresectable exocrine adenocarcinoma of the pancreas-A study within the Central European Society Anticancer Drug Research (CESAR) collaborative network. Br J Cancer 2012;107:280-6.
37. Rudolph D, Steegmaier M, Hoffmann M, Grauert M, Baum A, Quant J, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 2009;15: 3094-102.
38. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, et al. The efficacy and safety of BI 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: Results from an openlabel, randomized phase II clinical trial. J Thorac Oncol 2010;5: 1060-7.
39. Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the S and G2 checkpoint to treat cancer. Drug Discov Today 2012; 17:194-202.
40. Dominguez-Kelly R, Martin Y, Koundrioukoff S, Tanenbaum ME, Smits VA, Medema RH, et al. Wee1 controls genomic stability during replication by regulating the Mus81-Eme1 endonuclease. J Cell Biol 2011;194:567-79.
41. WuCL, Kirley SD, Xiao H, Chuang Y, Chung DC, Zukerberg LR. Cables enhances cdk2 tyrosine 15 phosphorylation by Wee1, inhibits cell growth, and is lost in many human colon and squamous cancers. Cancer Res 2001;61:7325-32.
42. Wroble BN, Finkielstein CV, Sible JC. Wee1 kinase alters cyclin E/Cdk2 and promotes apoptosis during the early embryonic development of Xenopus laevis. BMC Dev Biol 2007;7:119.
43. Hansen DV, Loktev AV, Ban KH, Jackson PK. Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell 2004;15:5623-34.
44. Eckerdt F, Strebhardt K. Polo-like kinase 1: Target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 2006;66:6895-8.
45. Taylor WR, Stark GR. Regulation of the G2/M transition by p53. Oncogene 2001;20:1803-15.
46. Smits VA, Klompmaker R, Arnaud L, Rijksen G, Nigg EA, Medema RH. Polo-like kinase-1 is a target of the DNA damage checkpoint. Nat Cell Biol 2000;2:672-6.
47. Bahassiel M. Polo-like kinases and DNA damage checkpoint: Beyond the traditional mitotic functions. Exp Biol Med (Maywood) 2011;236: 648-57.